الفهرس 
Diabetic Peripheral NeuropathyOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Background: Plasma calprotectin is a persistent biomarker of insulin resistance (IR), gastroenteritis, and cardiovascular disease (CVD). Elevated plasma levels of calprotectin have been reported in a variety of chronic inflammatory conditions. Elevated calprotectin levels have been reported to predict microvascular alterations in type 2 diabetes (T2DM) patients.
Aim of the Work: To evaluate if there is a relationship between serum calprotectin and perioheral neuropathy in a sample of Egyptian type 2 Diabetic patients.
Patients and methods: This study is a case–control study that was conducted on 60 subjects their age ranging from 45- 60 years old, recruited from Endocrinology & metabolism outpatient clinic at Ain Shams University hospitals, divided into 3 groups, during the period from May to October 2020.
Results: There was highly statistically significant difference found between the three groups regarding HS CRP, S calprotectin,, HbA1c, FbG,2hrpp with (p-value 0.000).
Conclusion: High levels of calprotectin detected in type 2 diabetic patients with peripheral neuropathy suggest that this molecule may have a role in pathogenesis of neuroinflammation among these patients. Serum calprotectin levels in the future may be used as potential markers of its presence, severity and progression of the diabetic peripheral neuropathy. Therapeutic strategies for blocking S100A9 and its activity are recently under development in inflammatory diseases. Therefore, Diabetic neuropathy is associated with increased serum level of calprotectin